[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgery-oral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgery-oral":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100271846","composite-tissue-allotransplantation-of-the-face-anatomical-and-functional-evaluation-100271846",false,"NCT02818400","Composite Tissue Allotransplantation of the Face: Anatomical and Functional Evaluation","AFTC","Inclusion Criteria:\n\n* Patients with loss of unrepairable substance by conventional techniques shreds, at the front\n\nExclusion Criteria:\n\n* Facial lesions repaired by conventional reconstructive surgery techniques\n* History of malignancy in remission for less than 5 years\n* Malignant neoplasm undergoing changes\n* Severe psychiatric history\n* Patients above a score of 2 on the scale of the ASA (American Society of Anesthesiology)\n* Patients above a grade 1 in the classification NYHA ( New York Heart Association )\n* insufficient with renal creatinine clearance less than 70 mL \u002F min or presence of a proteinuria\n* Severe hypertension","ALL","18 Years","50 Years",{"count":20,"type":21},5,"ESTIMATED","INTERVENTIONAL",[24],"NA","In hindsight, the first \"face graft\" raises the fundamental problem of composite tissue allotransplantation (hand, larynx, abdominal wall, etc.) with the addition of specific technical and philosophical problems.\n\nBy proposing a prospective study concerning five new patients over the next three years, in the light of this first experience, the authors would like to confirm the surgical feasibility of this type of procedure, possibly extending it to other parts of the face (lateral third) and, like English and American teams, considering the possibility of total facial surface reconstruction.\n\nIn parallel, and while complying with the usual immunosuppression procedures, the deliberate choice of creating a microchimerism by the infusion of bone marrow stem cells (the origin and quantity of which will need to be determined) will be reaffirmed, in order to improve mucocutaneous tissue tolerance, while confirming the safety of this type of approach.\n\nFive new cases will also provide observations for the many new fields of research developing around composite tissue transplants (neurophysiology, skin histopathology, psychiatry, haematology, immunology, etc.).",[27],"Surgery, Oral",[29,30,31,32,33,34],"maxillofacial surgery","face graft","composite tissue","stem cell infusion","allotransplantation","microsurgery","RECRUITING","2026-05-12",{"date":38,"type":39},"2026-05-13","ACTUAL",{"date":41,"type":39},"2009-11",{"date":43,"type":21},"2026-12",{"name":45,"class":46},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":47},"100632294","phase-2-a-study-of-ly4515100-in-participants-with-pain-following-third-molar-removal-100632294","NCT07511816","A Study of LY4515100 in Participants With Pain Following Third Molar Removal","A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Oral Dose of LY4515100, in Participants Experiencing Moderate-to-Severe Acute Pain Following Surgical Removal of Impacted Third Molars","Inclusion Criteria:\n\n* Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg\u002Fm²) inclusive.\n* Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray.\n\nExclusion Criteria:\n\n* Prior dental surgery within 60 days before screening or history of other surgical procedures that could confound surgery or postoperative procedures.\n* Diagnosis of chronic pain conditions that could confound postsurgical pain reporting in the opinion of the investigator.\n* Positive urine drug screen or alcohol test during screening or on the day of surgery.\n* Evidence or history of any other clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, or neurologic diseases, in the opinion of the investigator, within the last 5 years.\n* History of malignancy of any organ system treated or untreated, within 5 years prior to consent. The only exceptions are previous in situ carcinoma of the cervix, localized basal cell carcinoma of the skin, or localized squamous carcinoma of the skin if the participant has been treated and is considered cured.","40 Years",{"count":57,"type":21},212,[59],"PHASE2","The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.",[62,63,64,27],"Acute Pain","Molar","Molar, Third","2026-04-27",{"date":67,"type":39},"2026-05-01",{"date":69,"type":39},"2026-04-01",{"date":43,"type":21},{"name":72,"class":73},"Eli Lilly and Company","INDUSTRY"]